Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

(2020) John Timmerman et al.   AMERICAN JOURNAL OF HEMATOLOGY

A T CELL REDIRECTING BISPECIFIC G-PROTEIN COUPLED RECEPTOR CLASS 5 MEMBER DxCD3 ANTIBODY TO TREAT MULTIPLE MYELOMA

(2020) Kodandaram Pillarisetti et al.   BLOOD

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity

(2020) Yik Andy Yeung et al.   MOLECULAR THERAPY

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

(2020) Patrick J. Engelberts et al.   EBioMedicine

Immunotherapy in Hodgkin and Non-Hodgkin Lymphoma: Innate, Adaptive and Targeted Immunological Strategies

(2020) Aung M. Tun et al.   CANCER TREATMENT REVIEWS

How to select IgG subclasses in developing anti-tumor therapeutic antibodies

(2020) Jifeng Yu et al.   Journal of Hematology & Oncology

T cell-engaging therapies — BiTEs and beyond

(2020) Maria-Elisabeth Goebeler et al.   Nature Reviews Clinical Oncology

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

(2020) Nancy L. Bartlett et al.   BLOOD

Bi 38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicities for the treatment of multiple myeloma.

(2020) Maxime Fayon et al.   HAEMATOLOGICA

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions

(2020) Bachar Samra et al.   Journal of Hematology & Oncology

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia

(2020) Geoffrey L Uy et al.   BLOOD

BCMA-targeted immunotherapy for multiple myeloma

(2020) Bo Yu et al.   Journal of Hematology & Oncology

Myelodysplastic Syndromes

(2020) Mario Cazzola   NEW ENGLAND JOURNAL OF MEDICINE

Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

(2020) Robin Foà et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia

(2020) Xiaoya Yun et al.   Biomarker Research

The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models

(2020) Shih-Feng Cho et al.   Blood Advances

AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys

(2020) Rebecca L. Goldstein et al.   Blood Advances

Targeting the Wnt/β-catenin signaling pathway in cancer

(2020) Ya Zhang et al.   Journal of Hematology & Oncology

Targeting FLT3 mutations in AML: review of current knowledge and evidence

(2019) Naval Daver et al.   LEUKEMIA

Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment

(2019) Ibrahim Aldoss et al.   Current Oncology Reports

Mechanisms of drug resistance in acute myeloid leukemia

(2019) Jing Zhang et al.   OncoTargets and Therapy

Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T Cell-Recruiting Antibody Optimized for Cytotoxicity and Cytokine Release

(2019) Christina L. Zuch de Zafra et al.   CLINICAL CANCER RESEARCH

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

(2019) Anthony S. Stein et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions

(2019) Li Lu et al.   MOLECULAR IMMUNOLOGY

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma

(2019) Yu-Tzu Tai et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis

(2019) Pieter Fokko van Loo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Novel and emerging therapies for B cell lymphoma

(2019) Sabarish Ayyappan et al.   Journal of Hematology & Oncology

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11

(2019) Johannes Duell et al.   JOURNAL OF IMMUNOTHERAPY

Anti-GPRC5D/CD3 bispecific T cell-redirecting antibody for the treatment of multiple myeloma

(2019) Tatsushi Kodama et al.   MOLECULAR CANCER THERAPEUTICS

Maintenance therapy in AML: The past, the present and the future

(2019) Matteo Molica et al.   AMERICAN JOURNAL OF HEMATOLOGY

FLT3 overexpression in acute leukaemias: New insights into the search for molecular mechanisms

(2019) Caroline Pires Poubel et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies

(2019) Testa et al.   Cancers

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia

(2019) Alessandro Rambaldi et al.   CANCER

Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events

(2019) Matthias Klinger et al.   CANCER RESEARCH

Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia

(2019) Nicola Gökbuget et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

(2018) Nicola Gökbuget et al.   BLOOD

Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review

(2018) Atlantis Russ et al.   BLOOD REVIEWS

Bispecific antibody based therapeutics: Strengths and challenges

(2018) Archana Thakur et al.   BLOOD REVIEWS

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

(2018) Olivia Campagne et al.   CLINICAL CANCER RESEARCH

CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematological malignancies

(2018) Marina Bacac et al.   CLINICAL CANCER RESEARCH

Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia

(2018) Ya Zhang et al.   ONCOGENE

Bispecific antibodies for cancer therapy: A review

(2018) Anuradha Krishnamurthy et al.   PHARMACOLOGY & THERAPEUTICS

Myelodysplastic syndromes current treatment algorithm 2018

(2018) David P. Steensma   Blood Cancer Journal

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms

(2018) Paola Circosta et al.   OncoImmunology

Cytokine release syndrome

(2018) Alexander Shimabukuro-Vornhagen et al.   Journal for ImmunoTherapy of Cancer

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors

(2018) Anthony S. Stein et al.   ANNALS OF HEMATOLOGY

Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party

(2018) Sung-Hoon Jung et al.   ANNALS OF HEMATOLOGY

Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells

(2018) Todd A. Braciak et al.   OncoImmunology

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia

(2018) Monika Herrmann et al.   BLOOD

Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?

(2018) Yuxin Liu et al.   BLOOD REVIEWS

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Engineering therapeutic bispecific antibodies using CrossMab technology

(2018) Christian Klein et al.   METHODS

LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII

(2018) Takumi Maruhashi et al.   NATURE IMMUNOLOGY

Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody

(2018) Danbee Ha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells

(2018) Regina Jitschin et al.   Journal for ImmunoTherapy of Cancer

Recent advances in the development of novel protein scaffolds based therapeutics

(2017) Asim Azhar et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

(2017) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

The making of bispecific antibodies

(2017) Ulrich Brinkmann et al.   mAbs

NKG2D Ligand–Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors

(2017) Claire Godbersen et al.   MOLECULAR CANCER THERAPEUTICS

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia

(2017) Donald A. Berry et al.   JAMA Oncology

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

(2016) A. Viardot et al.   BLOOD

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

(2016) Saad Z. Usmani et al.   BLOOD

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

(2016) Friederike Braig et al.   BLOOD

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

(2016) U. Reusch et al.   CLINICAL CANCER RESEARCH

Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma

(2016) E. Sanchez et al.   CLINICAL CANCER RESEARCH

New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma

(2016) Ola Landgren et al.   CLINICAL CANCER RESEARCH

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

(2016) Min Zhu et al.   CLINICAL PHARMACOKINETICS

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

(2016) N. Gokbuget et al.   HAEMATOLOGICA

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

(2016) Maria-Elisabeth Goebeler et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2016) S Hipp et al.   LEUKEMIA

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

(2016) N. Gokbuget et al.   HAEMATOLOGICA

Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia

(2016) N. V. Frey et al.   Hematology-American Society of Hematology Education Program

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform

(2015) M. Al-Hussaini et al.   BLOOD

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

(2015) Y. Chalandon et al.   BLOOD

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

(2015) A. Rothe et al.   BLOOD

The double-edged sword: Neurotoxicity of chemotherapy

(2015) Rajiv S. Magge et al.   BLOOD REVIEWS

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

(2015) Thomas Köhnke et al.   Journal of Hematology & Oncology

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

(2015) C Krupka et al.   LEUKEMIA

T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion

(2015) Zhi-Zhang Yang et al.   LEUKEMIA & LYMPHOMA

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells

(2015) Uwe Reusch et al.   mAbs

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

(2015) Tao Dao et al.   NATURE BIOTECHNOLOGY

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

(2014) Anita Kumar et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bispecific T-cell engagers for cancer immunotherapy

(2014) Amelia M Huehls et al.   IMMUNOLOGY AND CELL BIOLOGY

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system

(2014) Yiren Xu et al.   mAbs

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface

(2014) Steven M Lewis et al.   NATURE BIOTECHNOLOGY

Treating acute myeloid leukemia in older adults

(2014) E. S. Wang   Hematology-American Society of Hematology Education Program

The Immunological Synapse

(2014) M. L. Dustin   Cancer Immunology Research

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

Regulatory Roles of the Tumor Necrosis Factor Receptor BCMA

(2013) Christine M. Coquery et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells

(2013) R. Wong et al.   HAEMATOLOGICA

Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies

(2013) Christoph Spiess et al.   NATURE BIOTECHNOLOGY

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

(2012) R. B. Walter et al.   BLOOD

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

(2012) Eric Sanchez et al.   BRITISH JOURNAL OF HAEMATOLOGY

Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma

(2012) Johanna Atamaniuk et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

RECRUIT-TandAbs®: harnessing the immune system to kill cancer cells

(2012) Fionnuala McAleese et al.   Future Oncology

Blinatumomab: A historical perspective

(2012) Dirk Nagorsen et al.   PHARMACOLOGY & THERAPEUTICS

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up

(2011) Hanne Ø. Larsen et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

(2011) Dirk Nagorsen et al.   EXPERIMENTAL CELL RESEARCH

Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells

(2011) Jerome Thiery et al.   NATURE IMMUNOLOGY

Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

(2010) Claudia Bluemel et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion

(2010) Syd Johnson et al.   JOURNAL OF MOLECULAR BIOLOGY

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

(2009) Liqing Jin et al.   Cell Stem Cell

Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia

(2009) X. Zhao et al.   HAEMATOLOGICA

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

(2009) John Koreth et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Functions and molecular mechanisms of the CD47–SIRPα signalling pathway

(2009) Takashi Matozaki et al.   TRENDS IN CELL BIOLOGY

Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

(2008) Fabio Malavasi et al.   PHYSIOLOGICAL REVIEWS

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE

CD38 at the junction between prognostic marker and therapeutic target

(2008) Silvia Deaglio et al.   TRENDS IN MOLECULAR MEDICINE